Markets

La Jolla Pharmaceutical Hits 80-Plus Relative Strength Rating Benchmark

Shutterstock photo

On Wednesday, La Jolla Pharmaceutical ( LJPC ) reached an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before.

[ibd-display-video id=2102289 width=50 float=left autostart=true] IBD's unique rating tracks share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.

History shows that the top-performing stocks typically have an 80 or better RS Rating in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

La Jolla Pharmaceutical is working on a consolidation with a 39.38 entry . See if it can break out in heavy volume.

La Jolla Pharmaceutical showed 3% earnings growth in the latest quarterly report, while sales growth came in at -100%.

La Jolla Pharmaceutical earns the No. 117 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Vertex Pharmaceuticals ( VRTX ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Rising Relative Strength?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VRTX CORT RS LJPC LGND

Other Topics

Stocks

Latest Markets Videos